Roth Capital steps to the sidelines on Peregrine Pharmaceuticals (PPHM -79%), downgrading it to...

|About: Peregrine Pharmaceuticals Inc. (PPHM)|By:, SA News Editor

Roth Capital steps to the sidelines on Peregrine Pharmaceuticals (PPHM -79%), downgrading it to Neutral and removing it from its Focus List due to the uncertainty over the discrepancies in its Phase II study of bavituximab. The firm also skewered its price target on the shares, slashing it to $0.70 from $9.